Khosla Rachna's most recent trade in AMGEN Inc. was a trade of 1,500 Common Stock done at an average price of $289.7 . Disclosure was reported to the exchange on June 5, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Amgen | Rachna Khosla | SVP, Business Development | Sale of securities on an exchange or to another person at price $ 289.68 per share. | 05 Jun 2025 | 1,500 | 8,162 (0%) | 0% | 289.7 | 434,520 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 3,943 | 3,943 | - | - | Nqso (Right to Buy) | |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 May 2025 | 610 | 9,662 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 110 | 9,156 (0%) | 0% | 283.8 | 31,216 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 283.78 per share. | 02 May 2025 | 104 | 9,052 (0%) | 0% | 283.8 | 29,513 | Common Stock |
| Amgen | Khosla Rachna | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 288.55 per share. | 30 Apr 2025 | 74 | 9,266 (0%) | 0% | 288.6 | 21,353 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 313.71 per share. | 17 Mar 2025 | 489 | 9,340 (0%) | 0% | 313.7 | 153,404 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 1,403 | 9,802 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 316.91 per share. | 05 Nov 2024 | 212 | 8,383 (0%) | 0% | 316.9 | 67,185 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 3,461 | 3,461 | - | - | Nqso (Right to Buy) | |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 532 | 8,559 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 311.29 per share. | 05 May 2024 | 41 | 8,027 (0%) | 0% | 311.3 | 12,763 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 277.36 per share. | 02 May 2024 | 74 | 8,068 (0%) | 0% | 277.4 | 20,525 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 276.38 per share. | 30 Apr 2024 | 48 | 8,142 (0%) | 0% | 276.4 | 13,266 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 268.87 per share. | 18 Mar 2024 | 438 | 8,190 (0%) | 0% | 268.9 | 117,765 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2024 | 1,256 | 8,597 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 231.90 per share. | 05 May 2023 | 39 | 7,581 (0%) | 0% | 231.9 | 9,044 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 5,016 | 5,016 | - | - | Nqso (Right to Buy) | |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2023 | 593 | 7,677 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.96 per share. | 02 May 2023 | 57 | 7,620 (0%) | 0% | 236.0 | 13,450 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 239.74 per share. | 30 Apr 2023 | 47 | 7,084 (0%) | 0% | 239.7 | 11,268 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 234.57 per share. | 17 Mar 2023 | 241 | 7,103 (0%) | 0% | 234.6 | 56,531 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Mar 2023 | 687 | 7,338 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Sale of securities on an exchange or to another person at price $ 292.90 per share. | 09 Nov 2022 | 387 | 6,630 (0%) | 0% | 292.9 | 113,352 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 269.04 per share. | 05 Nov 2022 | 168 | 7,017 (0%) | 0% | 269.0 | 45,199 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 247.47 per share. | 31 Jul 2022 | 217 | 7,158 (0%) | 0% | 247.5 | 53,701 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 236.11 per share. | 05 May 2022 | 37 | 7,344 (0%) | 0% | 236.1 | 8,736 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 4,949 | 4,949 | - | - | Nqso (Right to Buy) | |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 May 2022 | 606 | 7,434 (0%) | 0% | 0 | Common Stock | |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 230.92 per share. | 02 May 2022 | 53 | 7,381 (0%) | 0% | 230.9 | 12,239 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 249.86 per share. | 27 Apr 2022 | 28 | 6,828 (0%) | 0% | 249.9 | 6,996 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Payment of exercise price or tax liability using portion of securities received from the company at price $ 235.86 per share. | 18 Mar 2022 | 322 | 6,856 (0%) | 0% | 235.9 | 75,947 | Common Stock |
| Amgen | Rachna Khosla | SVP, Business Development | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2022 | 923 | 7,139 (0%) | 0% | 0 | Common Stock |